ArticleScience (New York, N.Y.)2016
The epigenetic landscape of T cell exhaustion.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03941496 (Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy), which is not on this map. Cited by 642 papers.
0numbers the graph read from it
0cells of the map it votes in
642citing papers in PubMed
39.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03941496 phase1 / phase2withdrawnnot on this mapstarted 2022, after this paper: background citation
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Who cites it
642 citing papers in PubMed, 928 citations in OpenAlex.
- Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.Nature communications · 2026Trial
- Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.Nature medicine · 2024Trial
- Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response.Science advances · 2026Article
- In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy.Cancer immunology research · 2026Article
- CD39 on CD8European journal of immunology · 2026Review
- High ZFP36 Family Expression in Exhausted T Cells Is Associated With Impaired Antitumor Effector Function.Cancer science · 2026Article
- The Epigenetic Architecture of Classical Hodgkin Lymphoma: Lineage Erasure, Immune Escape, and Therapeutic Reprogramming.Medicina (Kaunas, Lithuania) · 2026Review
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues.Stem cell reports · 2026Article
- Multiscale modeling of T cell exhaustion: A mathematical framework integrating continuous dynamics with spatial heterogeneity.PLoS computational biology · 2026Article
- Candidate MicroRNA Regulatory Axes in Melanoma CD8+ T Cell Exhaustion: A Network-Based In Silico Stratification.Cureus · 2026Article
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
- Wnt/β-catenin signaling in hepatocellular carcinoma: a key player in resistance to targeted and immunotherapies.Carcinogenesis · 2026Review
- Nuclear factor of activated T cells as a driver of tumor progression and a target for precision therapy.Animal models and experimental medicine · 2026Review
- Immunosenescence in systemic and multi-organ aging: mechanisms, inter-organ crosstalk, and translational opportunities.npj aging · 2026Review
- Azacytidine restores T cell function in AML by modulating DNA methylation.bioRxiv : the preprint server for biology · 2026Article
- Epigenetic conditioning improves sequence-based modeling of gene regulation across cell types and alleles.bioRxiv : the preprint server for biology · 2026Article
- Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines · 2026Review
- RECOMBINE identifies recurrent composite markers of cell types and states.Genome research · 2026Article
582 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 6 institutions in 1 country.
Debattama R SenDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
James KaminskiCenter for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
R Anthony BarnitzDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Makoto KurachiInstitute of Immunology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ulrike GerdemannDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Kathleen B YatesDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Hsiao-Wei TsaoDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jernej GodecDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Martin W LaFleurDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Flavian D BrownDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Pierre TonnerreGastrointestinal Unit and Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Raymond T ChungGastrointestinal Unit and Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Damien C TullyRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, MA 02139, USA.
Todd M AllenRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, MA 02139, USA.
Nicole FrahmVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Georg M LauerGastrointestinal Unit and Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
E John WherryInstitute of Immunology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Nir YosefCenter for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA. niryosef@berkeley.edu nicholas_haining@dfci.harvard.edu.
W Nicholas HainingDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. niryosef@berkeley.edu nicholas_haining@dfci.harvard.edu.
Dana-Farber Cancer Institute · USUniversity of California, Berkeley · USUniversity of Pennsylvania · USFred Hutch Cancer Center · USHarvard University · USMassachusetts Institute of Technology · US
Funding
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MVirology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GEORG Michael LAUER · 2009 to 2026
$48.1MPilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3MRules of gene expression modeled on human dendritic cell response to pathogensU01HG007910 · NHGRI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GARBER, MANUEL, LUBAN, JEREMY · 2015 to 2017
$6.1MFunctional genomic analysis of the CD8 T cell response to HIV vaccines inR01AI091493 · NIAID · DANA-FARBER CANCER INST · PI AHMED, RAFI, HAINING, WILLIAM NICHOLAS · 2010 to 2015
$4.9MClassification of Cortical Neurons by Single Cell TranscriptomicsU01MH105979 · NIMH · UNIVERSITY OF CALIFORNIA BERKELEY · PI NGAI, JOHN J. · 2014 to 2016
$4.5MTesting the role of BATF as a pioneer transcription factor in effector T cellsR01AI115712 · NIAID · DANA-FARBER CANCER INST · PI KADOCH, CIGALL, WHERRY, E. JOHN · 2015 to 2019
$2.9MRole of CTL avidity in epitope variant recognition and immune control of HIVR21AI078809 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FRAHM, NICOLE · 2009 to 2010
$484kNHGRI NIH HHS U01 HG007910NIAID NIH HHS R01 AI091493NIAID NIH HHS R01 AI115712NIAID NIH HHS R21 AI078809NIAID NIH HHS U19 AI082630NIAID NIH HHS UM1 AI068618NIDDK NIH HHS P30 DK043351NIMH NIH HHS U01 MH105979
Abstract
Exhausted T cells in cancer and chronic viral infection express distinctive patterns of genes, including sustained expression of programmed cell death protein 1 (PD-1). However, the regulation of gene expression in exhausted T cells is poorly understood. Here, we define the accessible chromatin landscape in exhausted CD8
Indexed as
Enhancer Elements, GeneticEpigenesis, GeneticAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesCell LineageChromatinChronic DiseaseDisease Models, AnimalGene EditingHepatitis C, ChronicHIV InfectionsHumansImmunologic MemoryImmunotherapyLymphocytic ChoriomeningitisB7-H1 AntigenChromatinSOXB1 Transcription FactorsT-bet Transcription FactorT-Box Domain Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03941496ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.